Uppsala, Sweden, January 29th, 2010
Beactica AB, the leading Swedish fragment-based drug discovery company, today announced a new investment and the addition of Innovationsbron AB to its shareholders. They join Uppsala University Holding Company and the founders as continuing investors. The funds will be used to finance the progression of Beactica’s internal drug discovery pipeline.
"We are delighted to welcome Innovationsbron as a shareholder” said Beactica CEO, Dr Per Källblad. "Innovationsbron has a strong track record in the commercialization of research concepts and their wide expertise will provide a valuable contribution as we move forward”.
VP Regional Director Mid-Sweden at Innovationsbron, Tomas Nygren, said "From day one Beactica has successfully delivered high-value services to a growing number of global life-science companies. Supporting Beactica in enhancing their drug discovery operations perfectly matches our mission to turn excellent research and innovation into business.”
For additional information, please contact Dr Per Källblad, Beactica CEO, +46 18 56 08 80, or Tomas Nygren, VP Regional Director Mid-Sweden at Innovationsbron AB, +46 18 51 05 99.
Sign up for the Beactica newsletter to receive our latest news and updates